Aim Immunotech Inc.

  • Health Care
  • Biotechnology: Biological Products (No Diagnostic Substances)
  • www.aimimmuno.com
  • Moat Score
  • Market Cap $11.50M
  • PE -0
  • Debt $5.89M
  • Cash $915.00K
  • EV $16.48M
  • FCF $NaN

Earnings

loading chart...

Sales & Net Margins

loading chart...
Earnings-$23.93M
EBIT-$27.92M
ROE-822%
ROA-205%
Equity$2.91M
Growth Stability1
PE-0.48
PB3.95
P/S60.54
Price/Cash0.08
Debt/Equity2.02
Net Margins-9K%
Op. Margins-15K%
Sales Growth YoY-24%
Sales Growth QoQ-30%
Sales CAGR-0%
Equity CAGR3%
Earnings Growth YoY-53%
Earnings Growth QoQ102%
Sales CAGR 5Y3%
Equity CAGR 5Y-40%
Earnings CAGR 3Y19%
Sales CAGR 3Y19%
Equity CAGR 3Y-66%
Market Cap$11.50M
Revenue$190.00K
Assets$13.59M
Total Debt$5.89M
Cash$915.00K
Shares Outstanding53.35M
EV16.48M
Moat Score0%
Working Capital-2.53M
Current Ratio0.75
Shares Growth 3y3%
Equity Growth QoQ-52%
Equity Growth YoY-87%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...
AIM ImmunoTech Inc is an immuno-pharma company focused on research and development of therapeutics to treat immune disorders, viral and cancer diseases. AIM's flagship products include Ampligen (Rintatolimod), a drug of large macromolecular RNA molecules for cancer and viral diseases and drug Alferon N Injection for a category of STD infection. Clinical trials of Ampligen include studies of cancer patients with renal cell carcinoma, malignant melanoma, colorectal cancer, advanced recurrent ovarian cancer and triple negative metastatic breast cancer. The company is also advancing Ampligen as a potential treatment for COVID-19. FDA has authorized the first human trial assessing the safety and effectiveness of Ampligen in combination with interferon alfa-2b, in cancer patients with COVID-19.

SEC Filings

Direct access to Aim Immunotech Inc. (AIM) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

  • 2024
    • 10-Q Sep 30
    • 10-Q Jun 30
    • 10-Q Mar 31
  • 2023
    • 10-K Dec 31
    • 10-Q Sep 30
    • 10-Q Jun 30
    • 10-Q Mar 31
  • 2022
    • 10-K Dec 31
    • 10-Q Sep 30
    • 10-Q Jun 30
    • 10-Q Mar 31

Sector Comparison

How does Aim Immunotech Inc. compare to its competitors?

Loading chart...

Peter Lynch's Chart

This chart shows the current pricing of Aim Immunotech Inc. compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

loading chart...

Aim Immunotech Inc. Discounted Cash Flow

Fully customizable DCF calculator online for Aim Immunotech Inc..

0
012345678910TV
fcf$0$0$0$0$0$0$0$0$0$0$0$0
DCF$0$0$0$0$0$0$0$0$0$0$0
Value$0

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years12/201412/201512/201612/201712/201812/201912/202005/202112/202112/202212/2023TTM
Net Margins-9K%-11K%-8K%-2K%-3K%-7K%-9K%--14K%-14K%-14K%-9K%
ROA--73%-73%-80%-83%-62%-23%--33%-49%-165%-205%
ROE--75%-48%-95%-190%-74%-23%--34%-51%-283%-822%

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years12/201412/201512/201612/201712/201812/201912/202005/202112/202112/202212/2023TTM
Debt over FCF-----0.55-0.28-0.22-----
Debt over Equity----1.150.20.04----2.02
Growth Stability-----------1

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years12/201412/201512/201612/201712/201812/201912/202005/202112/202112/202212/2023CAGR 5Y
Revenue YoY growth--32%-31%375%-16%-62%16%--4%43%3%
Earnings YoY growth--13%-51%10%19%-3%51%--2%49%-
Equity YoY growth--19%-24%-44%-41%149%375%---32%-73%-40%
FCF YoY growth-13%-54%6%34%-15%14%--16%--